NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand

Learn more about cookies at :

October 7, 2019 | List develops EMY exoskeleton to restore mobility in tetraplegic patients

clinatec 1 2
The four-limb exoskeleton controlled by the patient during the BCI project at Clinatec ©Clinatec

The breakthrough

For the first time ever, a tetraplegic patient was able to walk and control his two upper limbs using a neuroprosthetic system that gathers, transmits, and decodes brain signals in real time to control an exoskeleton built by List, a CEA Tech institute and member of the Carnot Network. The results of Clinatec’s Brain Computer Interface (BCI) clinical trial were published on October 4, 2019 in The Lancet Neurology. The trials were carried out at Clinatec in cooperation with the CEA and Grenoble-Alpes University Medical Center. The CEA and Clinatec held a press conference on October 7, and this step forward for patients was picked up numerous times by the media.

List’s challenge

For List’s ExoBCI team, dispatched to Grenoble near where the clinical work is being done, the EMY (Enhanced Mobility) exoskeleton is the culmination of several years of development and integration work on List’s reversible actuator and command-control technology bricks. EMY was designed specifically around the fact that it would have to interact with a tetraplegic patient to enable the patient to move around safely. List design software also contributed to this exciting advance by ensuring that the electronics used to run the exoskeleton are safe.

Learn more in the CEA press release and media coverage of this breakthrough: